Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients

This study has been completed.
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
University of Pittsburgh Identifier:
First received: August 12, 2011
Last updated: December 5, 2014
Last verified: December 2014
This is a single center, observational study of posaconazole PK sampling in lung transplant recipients. The patients enrolled will have up to 6 (3ml) pk samples (a total of 18 ml) and one 10ml blood sample for a total collection of 28ml of blood obtained over the entire study. In addition, the investigators will collect medical record information and any excess BAL samples available during the study (tests done as part of the patient's clinical care and the samples would have been discarded once diagnosis was made).

Condition Intervention
Lung Transplant Infection
Fungal Infection
Other: collection of blood samples for PK testing

Study Type: Interventional
Study Design: Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients

Resource links provided by NLM:

Further study details as provided by University of Pittsburgh:

Primary Outcome Measures:
  • measure the levels of posaconazole post dosing [ Time Frame: 24 hours after dosing ] [ Designated as safety issue: No ]
    pk samples will be obtained around dosing of medication and then analyzed for posaconazole levels

Secondary Outcome Measures:
  • determine the posaconazole concentration within the pulmonary epithelial lining fluid (ELF) and alveolar cells [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Enrollment: 20
Study Start Date: October 2011
Study Completion Date: December 2014
Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 'collection of blood samples for PK testing'
collection of PK samples around a dosing of Posaconazole
Other: collection of blood samples for PK testing
PK samples collected around dosing of posaconazole

Detailed Description:
PK blood samples will be obtained around a clinical dosing of posaconazole

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age and older receiving posaconazole post transplant as part of their care received a lung transplant

Exclusion Criteria:

  • must meet inclusion criteria
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01419678

United States, Pennsylvania
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
University of Pittsburgh
Merck Sharp & Dohme Corp.
Principal Investigator: Ryan Shields, Pharm D UPMC
  More Information

Responsible Party: University of Pittsburgh Identifier: NCT01419678     History of Changes
Other Study ID Numbers: PRO10110232 
Study First Received: August 12, 2011
Last Updated: December 5, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by University of Pittsburgh:
PK blood sampling

Additional relevant MeSH terms:
Communicable Diseases
Antifungal Agents
Anti-Infective Agents
Trypanocidal Agents
Antiprotozoal Agents
Antiparasitic Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on October 21, 2016